In In re Copaxone Consolidated Cases, the Federal Circuit affirmed the district court decision finding four patents directed to a specific dosing regimen for using COPAXONE® 40 mg/ml to treat patients ...

Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...

Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...

This dose of Copaxone allows three times a week subcutaneous administration as compared to the daily administration schedule for the currently available formulation (20 mg/mL). The lower frequency of ...

A year ago, the Food and Drug Administration quietly posted a public notice that it wanted to hire an independent lab to test a generic drug that it had already approved. FDA wanted to make sure the ...

PreCISe Data Presented at World Congress on Treatment and Research in Multiple Sclerosis JERUSALEM--(BUSINESS WIRE)--New data from PreCISe, in clinically isolated syndrome patients, have demonstrated ...

Recent research has led to a new treatment regimen that will affect millions of multiple sclerosis patients around the world. The U.S. Food and Drug Administration has approved a new drug application ...

Teva Pharmaceutical Industries Ltd has lost a bid to force the U.S. Food and Drug Administration to regulate its blockbuster multiple sclerosis drug Copaxone as a biologic drug, which would have ...

Teva reports FDA approval for three-times-a-week Copaxone 40 mg/mL. reported that FDA has approved the company’s supplemental new drug application for three-times-a-week Copaxone 40mg/mL, a new dose ...